Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.

Literature DB >> 21719882

Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.

Giovanni Barosi¹, Alberto Bosi, Maria P Abbracchio, Romano Danesi, Armando Genazzani, Paolo Corradini, Fabrizio Pane, Sante Tura.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2011 PMID： 21719882 PMCID： PMC3128210 DOI： 10.3324/haematol.2011.041210

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

25 in total

1. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer.

Authors: Cornelius F Waller; Vladimir F Semiglazov; Sergei Tjulandin; Dmitry Bentsion; Stephen Chan; Rodeina Challand
Journal: Onkologie Date: 2010-09-06

2. The NIH Consensus Development Program. The evolution of guidelines.

Authors: J H Ferguson
Journal: Int J Technol Assess Health Care Date: 1996 Impact factor: 2.188

Review 3. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.

Authors: Ywe J Looper
Journal: Curr Opin Drug Discov Devel Date: 2010-03

4. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Authors: Volker Wizemann; Boleslaw Rutkowski; Conrad Baldamus; Paul Scigalla; Rossen Koytchev
Journal: Curr Med Res Opin Date: 2008-03 Impact factor: 2.580

5. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.

Authors: M Haag-Weber; A Vetter; U Thyroff-Friesinger
Journal: Clin Nephrol Date: 2009-11 Impact factor: 0.975

6. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma.

Authors: Andreas Engert; Auro del Giglio; Peter Bias; Heinz Lubenau; Ulrich Gatzemeier; David Heigener
Journal: Onkologie Date: 2009-09-14

7. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia.

Authors: Valentina Tzekova; Georgi Mihaylov; Ivo Elezovic; Rossen Koytchev
Journal: Curr Med Res Opin Date: 2009-07 Impact factor: 2.580

Review 8. Biosimilar agents in oncology/haematology: from approval to practice.

Authors: Dietger Niederwieser; Stephan Schmitz
Journal: Eur J Haematol Date: 2011-01-25 Impact factor: 2.997

9. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

Authors: A del Giglio; A Eniu; D Ganea-Motan; E Topuzov; H Lubenau
Journal: BMC Cancer Date: 2008-11-12 Impact factor: 4.430

10. Biosimilar therapeutics-what do we need to consider?

Authors: Huub Schellekens
Journal: NDT Plus Date: 2009-01

17 in total

1. Ethical issues and concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilisation of stem cells in normal donors.

Authors: Giancarlo Maria Liumbruno; Carlo Petrini
Journal: Blood Transfus Date: 2012-03-29 Impact factor: 3.443

Review 2. The advent of biosimilar therapies in rheumatology--"O brave new world".

Authors: Morton A Scheinberg; Jonathan Kay
Journal: Nat Rev Rheumatol Date: 2012-06-05 Impact factor: 20.543

3. Biosimilars in 3D: definition, development and differentiation.

Authors: Ivo Abraham; Diana Sun; Alaa Bagalagel; Ahmed Altyar; Abdulaziz Mohammed; Soba Tharmarajah; Karen MacDonald
Journal: Bioengineered Date: 2013-05-16 Impact factor: 3.269

Review 4. Regulatory and clinical considerations for biosimilar oncology drugs.

Authors: Charles L Bennett; Brian Chen; Terhi Hermanson; Michael D Wyatt; Richard M Schulz; Peter Georgantopoulos; Samuel Kessler; Dennis W Raisch; Zaina P Qureshi; Z Kevin Lu; Bryan L Love; Virginia Noxon; Laura Bobolts; Melissa Armitage; John Bian; Paul Ray; Richard J Ablin; William J Hrushesky; Iain C Macdougall; Oliver Sartor; James O Armitage
Journal: Lancet Oncol Date: 2014-11-24 Impact factor: 41.316

Review 5. Erythropoietin or darbepoetin for patients with cancer.

Authors: Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal: Cochrane Database Syst Rev Date: 2012-12-12

6. Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury.

Authors: Natasha Irrera; Alessandra Bitto; Gabriele Pizzino; Mario Vaccaro; Francesco Squadrito; Mariarosaria Galeano; Francesco Stagno d'Alcontres; Ferdinando Stagno d'Alcontres; Michele Buemi; Letteria Minutoli; Michele Rosario Colonna; Domenica Altavilla
Journal: Biomed Res Int Date: 2015-06-04 Impact factor: 3.411

Review 7. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.

Authors: Mary Lynn Davis-Ajami; Jun Wu; Katherine Downton; Emilie Ludeman; Virginia Noxon
Journal: Biologics Date: 2014-04-16